Guardant Health Q3 revenue $143M (+22% YoY); raises FY 2023 guidance to $553-556M

Guardant Health, Inc.

2023-Q3 EPS reported -$2.66 revenue$408,894,000

GAAP net loss $86.1M ($0.73/share) vs $162M ($1.58) YoY; non-GAAP loss $79.2M ($0.67).
Clinical test volume 43,900 (+35% YoY); biopharma tests 7,500 (+11%).
Precision oncology revenue up 31% YoY; Medicare appeal payment of $3.6M included.
FY 2023 revenue guidance raised to $553-556M (23-24% growth); cash $1.2B.
Launched Guardant360 in Japan/China; Japan approval as CDx for ENHERTU.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Guardant Health, Inc. reported the quarter ended September 30, 2023 results: revenue $143.0 million, net income $86.1 million, EPS $0.73 per share. Guidance raised.

Period: the quarter ended September 30, 2023
Revenue: $143.0 million
Net income: $86.1 million
EPS: $0.73 per share
Guidance: raised
Result: reported results

Exact text from the filing

tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights • Revenue of $143.0 million for the third quarter of 2023, an increase of 22% over the third quarter of 2022 • Reported 43,900 tests to clinical customers and 7,500 tests to biopharmaceutical customers in

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Guardant Health, Inc. filing history →

Source: SEC EDGAR

accession 0001576280-23-000186

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.